AstraZeneca boosts its 2024 dividend to $3.10/share, reflecting confidence in performance. Shareholder concerns addressed as CEO compensation proposal approaches vote. Recent acquisitions and FDA approvals signal growth.
AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. Investor confidence remains a challenge amid stagnant shares and concerns over future growth. Soriot's strategic overhaul focuses on R&D and acquisitions.
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 50 points on Tuesday. The Dow traded up 0.63% to 39,034.59 while the NASDAQ rose 0.35% to 16,160.20. The S&P 500 also rose, gaining, 0.41% to 5,170.36.
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 200 points on Tuesday. The Dow traded up 0.54% to 39,001.22 while the NASDAQ fell 0.34% to 16,048.51. The S&P 500 also rose, gaining, 0.02% to 5,150.45.
U.S. stocks traded mixed this morning, with the Nasdaq Composite falling around 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.11% to 38,831.86 while the NASDAQ fell 0.63% to 16,001.30. The S&P 500 also fell, dropping, 0.28% to 5,135.12.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Shares of Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) rose sharply in today’s pre-market trading after the company agreed to be acquired by AstraZeneca for around $2 billion in cash.
AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer treatment with radioconjugates, including FPI-2265 for metastatic castration-resistant prostate cancer.
